Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medicinova (MNOV) Total Non-Current Liabilities (2021 - 2025)

Medicinova (MNOV) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a N/A change, with the full-year FY2025 number at $4.0 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $4.0 million for Q4 2025 at Medicinova, up from $3.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $4.7 million in Q3 2022 to a low of $2.3 million in Q1 2025.
  • A 5-year average of $3.4 million and a median of $3.1 million in 2021 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 36.5% in 2023, then rose 26.46% in 2025.
  • Medicinova's Total Non-Current Liabilities stood at $3.0 million in 2021, then skyrocketed by 55.87% to $4.7 million in 2022, then dropped by 26.41% to $3.5 million in 2023, then dropped by 19.6% to $2.8 million in 2024, then skyrocketed by 42.9% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for MNOV's Total Non-Current Liabilities are $4.0 million (Q4 2025), $3.5 million (Q3 2025), and $2.8 million (Q2 2025).